BioCentury | Feb 1, 2016
Clinical News

CBLB612: Phase II started

...Cleveland began a placebo-controlled, Russian Phase II trial to evaluate a single dose of CBLB612 given...
...by a development contract with the Russian government. Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Product: CBLB612...
BioCentury | Jul 20, 2015
Clinical News

Protectan CBLB612: Phase I data

...injections of 0.5-4 ug CBLB612 were generally well tolerated. The MTD was 4 ug CBLB612. CBLB612...
...neutrophil counts that lasted for about 20 hours. Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Product: Protectan CBLB612...
BioCentury | Aug 6, 2012
Company News

Cleveland BioLabs hematology news

...Russian Federation granted Cleveland a contract worth RUB139 million ($4.3 million) to fund development of Protectan CBLB612...
BioCentury | Sep 29, 2011
Distillery Therapeutics

Indication: Inflammation

...the ligands in mouse models of acute and chronic inflammation. Cleveland BioLabs Inc.'s TLR2 agonist Protectan CBLB612...
BioCentury | May 6, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...Therapeutics Ltd., is in preclinical development for inflammatory diseases and ischemia/reperfusion injury. Cleveland BioLabs Inc.'s Protectan CBLB612...
BioCentury | Sep 14, 2009
Company News

Cleveland BioLabs, Zhejiang Hisun Pharmaceutical deal

...Cleveland BioLabs granted Zhejiang Hisun an exclusive license to develop and commercialize Protectan CBLB612 in China for...
...for a 10% royalty on net sales, which may decrease to 5% if patents for CBLB612...
BioCentury | Apr 30, 2007
Clinical News

Cleveland BioLabs preclinical data

...In Rhesus macaques, a single dose of CBLB612 increased the number of progenitor stem cells in...
...by 20-fold. The company said the increase was comparable to 4 daily injections of G-CSF. CBLB612...
...from a component of the Mycoplasma cell wall. Cleveland BioLabs Inc. (CBLI), Cleveland, Ohio Product: CBLB612...
BioCentury | Jan 22, 2007
Company News

Cleveland BioLabs, Roswell Park Cancer Institute deal

CBLI will receive about $3 million from the institute and up to $2 million from other New York state agencies toward development of the company's CBLC 102 to treat cancer and CBLB 502 and CBLB...
BioCentury | Jan 15, 2007
Clinical News

Cleveland BioLabs preclinical data

...In mice, a single dose of CBLB612 increased the number of progenitor stem cells in the...
...by 3-fold within 24 hours and by 10-fold in the peripheral blood within 4 days. CBLB612...
...from a component of the Mycoplasma cell wall. Cleveland BioLabs Inc. (CBLI), Cleveland, Ohio Product: CBLB612...
Items per page:
1 - 9 of 9